A clinical study to determine the efficacy and safety of 1% methotrexate/Azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris.
Sutton
L
L
Cato Research Ltd., Durham, North Carolina 27713, USA. lysutton@cato.com
Swinehart
J M
JM
Cato
A
A
Kaplan
A S
AS
D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005782:Gels; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011537:Pruritus / Q000139:chemically induced; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects / Q000473:pathology; D016896:Treatment Outcome
D003879:Dermatologic Agents; D005782:Gels; D008727:Methotrexate